ATE65505T1 - Biologisch aktive fragmente von humanem antihaemophiliefaktor, methode zu ihrer herstellung und pharmazeutische praeparate. - Google Patents

Biologisch aktive fragmente von humanem antihaemophiliefaktor, methode zu ihrer herstellung und pharmazeutische praeparate.

Info

Publication number
ATE65505T1
ATE65505T1 AT86850067T AT86850067T ATE65505T1 AT E65505 T1 ATE65505 T1 AT E65505T1 AT 86850067 T AT86850067 T AT 86850067T AT 86850067 T AT86850067 T AT 86850067T AT E65505 T1 ATE65505 T1 AT E65505T1
Authority
AT
Austria
Prior art keywords
biologically active
pharmaceutical preparations
human anti
production
active fragments
Prior art date
Application number
AT86850067T
Other languages
English (en)
Inventor
Lars-Olof Andersson
Nanna Forsman
Kerstin Ebba Ingrid Larsen
Annelie Birgitta Lundin
Bohdan Pavlu
Inga Helena Sandberg
Karin Margareta Sewerin
Original Assignee
Kabivitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20359353&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE65505(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kabivitrum Ab filed Critical Kabivitrum Ab
Application granted granted Critical
Publication of ATE65505T1 publication Critical patent/ATE65505T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • E—FIXED CONSTRUCTIONS
    • E02—HYDRAULIC ENGINEERING; FOUNDATIONS; SOIL SHIFTING
    • E02D—FOUNDATIONS; EXCAVATIONS; EMBANKMENTS; UNDERGROUND OR UNDERWATER STRUCTURES
    • E02D31/00—Protective arrangements for foundations or foundation structures; Ground foundation measures for protecting the soil or the subsoil water, e.g. preventing or counteracting oil pollution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y10S530/83—Plasma; serum
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/10—Factor VIII, AHF; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Life Sciences & Earth Sciences (AREA)
  • Structural Engineering (AREA)
  • General Engineering & Computer Science (AREA)
  • Civil Engineering (AREA)
  • Paleontology (AREA)
  • Mining & Mineral Resources (AREA)
  • Hydrology & Water Resources (AREA)
  • Environmental & Geological Engineering (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT86850067T 1985-03-05 1986-02-24 Biologisch aktive fragmente von humanem antihaemophiliefaktor, methode zu ihrer herstellung und pharmazeutische praeparate. ATE65505T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE8501050A SE8501050D0 (sv) 1985-03-05 1985-03-05 Biologically active fragments of human antihemophilic factor and method for preparation thereof
EP86850067A EP0197901B1 (de) 1985-03-05 1986-02-24 Biologisch aktive Fragmente von humanem Antihämophiliefaktor, Methode zu ihrer Herstellung und pharmazeutische Präparate

Publications (1)

Publication Number Publication Date
ATE65505T1 true ATE65505T1 (de) 1991-08-15

Family

ID=20359353

Family Applications (1)

Application Number Title Priority Date Filing Date
AT86850067T ATE65505T1 (de) 1985-03-05 1986-02-24 Biologisch aktive fragmente von humanem antihaemophiliefaktor, methode zu ihrer herstellung und pharmazeutische praeparate.

Country Status (10)

Country Link
US (2) US4749780A (de)
EP (1) EP0197901B1 (de)
JP (1) JPS61205219A (de)
AT (1) ATE65505T1 (de)
CA (1) CA1341497C (de)
DE (1) DE3680368D1 (de)
DK (1) DK164282B (de)
HK (1) HK15293A (de)
SE (1) SE8501050D0 (de)
SG (1) SG1893G (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362854A (en) * 1983-03-31 1994-11-08 Scripps Clinic & Research Foundation Factor VIII coagulant polypeptides: method of making
US7138505B1 (en) 1984-01-12 2006-11-21 Novartis Vaccines And Diagnostics, Inc. Factor VIII:C nucleic acid molecules
SE8501050D0 (sv) * 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof
KR910006424B1 (ko) * 1985-08-21 1991-08-24 인코텍스 비.브이 편성브리프(brief) 제조방법
US5198349A (en) * 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
FI98829C (fi) * 1986-01-27 1997-08-25 Chiron Corp Menetelmä rekombinoidun proteiinikompleksin valmistamiseksi, jolla on humaanitekijä VIII:C-aktiivisuutta
US5422260A (en) * 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
EP0251843A1 (de) * 1986-06-06 1988-01-07 Transgene S.A. Verfahren zur Herstellung von Faktor VIII aus Säugerzellen
FR2613379B2 (fr) * 1987-04-03 1990-04-06 Transgene Sa Procede de preparation de fragments du facteur viii a partir de cellules de mammiferes
AU607927B2 (en) * 1986-06-24 1991-03-21 Nordisk Gentofte A/S A process for producing a coagulation active complex of factor viii fragments
US4980456A (en) * 1987-04-06 1990-12-25 Scripps Clinic And Research Foundation Recombinant factor VIIIC derived fragments
US5171844A (en) 1987-06-12 1992-12-15 Gist-Brocades N.W. Proteins with factor viii activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
EP0725708B1 (de) * 1992-04-06 1998-07-08 Pressmaster Tool Ab Crimp-werkzeug
KR100303872B1 (ko) * 1992-10-02 2001-11-22 크리스터 발스트룀, 프레드릭 베르그, 하랄트 알름 응고인자ⅷ제형을포함하는조성물,이것의제조방법및안정화제로서의계면활성제의사용방법
US5576291A (en) * 1993-09-13 1996-11-19 Baxter International Inc. Activated factor VIII as a therapeutic agent and method of treating factor VIII deficiency
SE9303601D0 (sv) * 1993-11-01 1993-11-01 Kabi Pharmacia Ab Improved cell cultivation method and medium
US6288030B1 (en) 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
IL113010A (en) * 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
SE9403915D0 (sv) * 1994-11-14 1994-11-14 Annelie Almstedt Process A
SE503424C2 (sv) * 1994-11-14 1996-06-10 Pharmacia Ab Process för rening av rekombinant koagulationsfaktor VIII
SE9501189D0 (sv) * 1995-03-31 1995-03-31 Pharmacia Ab Protein formulation
SE9503380D0 (sv) * 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
DE69740154D1 (de) 1996-04-24 2011-05-05 Univ Michigan Gegen Inaktivierung resistenter Faktor VIII
US8183344B2 (en) 1996-04-24 2012-05-22 University Of Michigan Inactivation resistant factor VIII
US5851800A (en) * 1996-05-14 1998-12-22 Pharmacia & Upjohn Ab Process for producing a protein
US6143179A (en) * 1996-06-24 2000-11-07 Kerckhoff-Klinik Gmbh Method for the affinity-chromatographic purification of factor VIII
US6197526B1 (en) 1999-01-04 2001-03-06 Dyax Corp. Polypeptides for binding human factor VIII and fragments of human factor VIII
US7112438B2 (en) * 1999-01-04 2006-09-26 Dyax Corp. Binding molecules for human factor VIII and factor VIII-like proteins
EP1038959A1 (de) 1999-03-17 2000-09-27 Aventis Behring Gesellschaft mit beschränkter Haftung Faktor VIII ohne B-Domän, der ein oder mehrere Insertionsstücke von verkürztem Intron I des Faktors IX enthält
SE9901379D0 (sv) 1999-04-19 1999-04-19 Pharmacia & Upjohn Ab Receptor structures
EP1233064A1 (de) 2001-02-09 2002-08-21 Aventis Behring Gesellschaft mit beschränkter Haftung Modifizierte Faktor VIII cDNA und deren Verwendung bei der Produktion von Faktor VIII
JP4361786B2 (ja) * 2001-06-14 2009-11-11 ザ スクリプス リサーチ インスティチュート 操作されたジスルフィド結合を有する安定化蛋白質
WO2003013244A1 (en) 2001-08-03 2003-02-20 The Government Of The United State Of America, As Represented By The Secretary Of The Department Of Health And Human Services Oral treatment of hemophilia
PL2574676T3 (pl) * 2007-12-27 2017-12-29 Baxalta GmbH Sposoby hodowli komórek
AU2012250568B2 (en) * 2011-05-05 2017-06-29 Matinas Biopharma Nanotechnologies, Inc. Cochleate compositions and methods of making and using same

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361509A (en) * 1981-12-14 1982-11-30 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies
US4495175A (en) * 1982-08-05 1985-01-22 University Of Rochester Preparation of highly purified human antihemophilic factor
WO1984003628A1 (en) * 1983-05-09 1984-09-27 Nordisk Insulinlab A concentrate of the antihemophilic factor viii and a process for producing it
NO167533C (no) * 1983-03-31 1991-11-13 Scripps Clinic Res Fremgangsmaate ved fremstilling av faktor viii koagulerende polypeptider og monoklonale antistoffer overfor disse.
DE10399011I1 (de) * 1984-01-12 2003-10-23 Chiron Corp F}r Fakton-VIIIc kodierende DNA-Sequenzen und ver wandte DNA-Konstruktionen
US4710381A (en) * 1984-05-22 1987-12-01 The Blood Center Of Southeastern Wisconsin Method for maintaining intact, non-degraded factor VIII/von-Willebrand factor during blood processing
US4543210A (en) * 1984-10-04 1985-09-24 Miles Laboratories, Inc. Process for producing a high purity antihemophilic factor concentrate
SE8501050D0 (sv) * 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof

Also Published As

Publication number Publication date
US4749780A (en) 1988-06-07
SE8501050D0 (sv) 1985-03-05
DK85786A (da) 1986-09-06
CA1341497C (en) 2006-02-14
DK164282B (da) 1992-06-01
JPH0547524B2 (de) 1993-07-19
US4877614A (en) 1989-10-31
SG1893G (en) 1993-06-11
JPS61205219A (ja) 1986-09-11
EP0197901B1 (de) 1991-07-24
EP0197901A1 (de) 1986-10-15
DK85786D0 (da) 1986-02-25
DE3680368D1 (de) 1991-08-29
HK15293A (en) 1993-03-05

Similar Documents

Publication Publication Date Title
DE3680368D1 (de) Biologisch aktive fragmente von humanem antihaemophiliefaktor, methode zu ihrer herstellung und pharmazeutische praeparate.
GEP20084347B (en) New derivatives of diphosphonic acid, method for their preparation and medicamentous form containing them
DE3680450D1 (de) Pharmazeutische zubereitungen von metoprolol mit kontrollierter wirkstoffabgabe, verfahren zu ihrer herstellung und verwendung dieser zubereitungen.
EE9900075A (et) 7a-( -aminoalküül)östratrieenid, nende valmistamise meetod, 7a-( -aminoalküül)östratrieene sisaldavad farmatseutilised preparaadid ja nende kasutamine ravimite valmistamiseks
DE3878918D1 (de) In-vivo-verabreichung von neurotransmittern durch implantierte eingekapselte zellen.
NO903542L (no) Frysetoerket blanding og fremgangsmaate for oral administrering av legemidler, naeringsmidler og biologisk aktive materialer.
DE3582439D1 (de) Mittel zur behandlung von herzerkrankungen.
DK352686A (da) Steril, farmaceutisk tpa-doseringsenhed og fremgangsmaade til fremstilling deraf, beholdersaet indeholdende tpa og doseringsenhedens anvendelse
IS3284A7 (is) Aðferð við framleiðslu á N1-súbstitúeruðum bensimidasólafleiðum til að nota við lækningar
DE3769707D1 (de) Therapeutisches system mit geregelter wirkstoffabgabe.
DE3682229D1 (de) Zur stimulierung der traenensekretion verwendbare pharmazeutische praeparate.
FR2601002B1 (fr) Composes aromatiques, leur procede de preparation et leur utilisation en medecine humaine et veterinaire et en cosmetique
HU907959D0 (en) Medical preparations
FI864164A7 (fi) Ihmis- -interferonin biologisesti aktiivisia johdoksia, niiden valmistus ja tällaisia johdoksia sisältävlääkkeitä.
BG44709A3 (bg) Метод за получаване на 9-хлор-1,5-бензотиазепинови производни
TW374085B (en) Novel piperidine derivatives, their preparation, pharmaceutical formulation and medical use
DE69534633D1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
ES8708241A1 (es) Un procedimiento para la preparacion de nuevos compuestos poliprenilicos
ATE69949T1 (de) Liposomen mit inhalativen allergenen zur behandlung von allergien, verfahren zu ihrer herstellung und diese enthaltende arzneimittel.
ES8704903A1 (es) Un metodo para preparar 6-cloro-2-metil-1h-2,3,4,5-tetrahidro-3-benzazepen-n-oxido.
DE3761561D1 (de) N,n-bis-(4-fluorophenyl)carbamoylacetohydroxamsaeure und diese enthaltende pharmazeutische zusammensetzungen.
ATE75938T1 (de) Enantiomere des propafenons enthaltende therapeutische mittel.
UA13475A (uk) СПОСІБ ОДЕРЖАННЯ 6-БЕНЗИЛОКСИЗАМІЩЕНИХ ІЗОПРОПІЛОВИХ ЕФІРІВ beta-КАРБОЛІН-3-КАРБОНОВОЇ КИСЛОТИ
Kudrin et al. Effect of tranquilizers on lipid peroxidation of biological membranes
UA5743C2 (uk) Препарат тканинних біологічно активних речовин, який має регенаторну дію, та спосіб його одержання

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EEIH Change in the person of patent owner
EEIH Change in the person of patent owner
RZN Patent revoked